Earnings Call Summary | Omnicell(OMCL.US) Q1 2024 Earnings Conference
Earnings Call Summary | Omnicell(OMCL.US) Q1 2024 Earnings Conference
The following is a summary of the Omnicell, Inc. (OMCL) Q1 2024 Earnings Call Transcript:
以下是Omnicell, Inc.（OMCL）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Omnicell reported Q1 2024 total revenues of $246 million, a decrease from both the previous quarter and the same period in the previous year.
Non-GAAP gross margin for Q1 2024 was 39.8%, a decrease of 380 basis points from the prior quarter, mainly due to lower revenue volume leverage.
Earnings per share were recorded at $0.03, with non-GAAP EBITDA standing at $11 million.
Omnicell's Q1 cost savings initiatives have been fully realized in the beginning of the first quarter with a smaller portion continuing throughout the year.
The company expects the 340B to generate about $30 million to $35 million annually.
Omnicell報告稱，2024年第一季度總收入爲2.46億美元，較上一季度和去年同期均有所下降。
2024年第一季度的非公認會計准則毛利率爲39.8％，比上一季度下降了380個點子，這主要是由於收入量槓桿率降低。
每股收益爲0.03美元，非公認會計准則息稅折舊攤銷前利潤爲1,100萬美元。
Omnicell第一季度的成本節約計劃已在第一季度初全面實現，其中一小部分將持續到全年。
該公司預計，340B每年將產生約3000萬至3500萬美元的收入。
Business Progress:
業務進展：
Omnicell announced the plan to exit one international product line to streamline operations and unlock shareholder value.
They are doing well with the initial XT Amplify program offerings with new customers and successful extensions of agreements.
They announced a new offering, EnlivenHealth, an analytics solution aimed to transform complex data into actionable insights, which has been performing well.
The XT Amplify program is anticipated to enhance long term growth.
They are considering divestiture as part of an ongoing plan but does not signify exit from international markets.
Omnicell has seen a good start to the year in its business Enliven with some good wins, indicating steady growth.
Omnicell宣佈計劃退出一項國際產品線，以簡化運營並釋放股東價值。
他們在向新客戶提供的初始XT Amplify計劃以及成功延長協議方面表現良好。
他們宣佈推出一項名爲EnlivenHealth的新產品，這是一種分析解決方案，旨在將複雜的數據轉化爲可操作的見解，一直表現良好。
預計XT Amplify計劃將促進長期增長。
他們正在考慮將資產剝離作爲正在進行的計劃的一部分，但並不表示退出國際市場。
Omnicell的業務Enliven今年開局良好，取得了一些不錯的勝利，表明穩步增長。
More details: Omnicell IR
更多詳情： Omnicell IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。